RYBELSUS Drug Patent Profile
✉ Email this page to a colleague
When do Rybelsus patents expire, and when can generic versions of Rybelsus launch?
Rybelsus is a drug marketed by Novo and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and fifty-one patent family members in thirty countries.
The generic ingredient in RYBELSUS is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.
DrugPatentWatch® Generic Entry Outlook for Rybelsus
Rybelsus was eligible for patent challenges on December 5, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 15, 2033. This may change due to patent challenges or generic licensing.
There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RYBELSUS?
- What are the global sales for RYBELSUS?
- What is Average Wholesale Price for RYBELSUS?
Summary for RYBELSUS
International Patents: | 151 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 16 |
Clinical Trials: | 9 |
Patent Applications: | 702 |
Drug Prices: | Drug price information for RYBELSUS |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYBELSUS |
What excipients (inactive ingredients) are in RYBELSUS? | RYBELSUS excipients list |
DailyMed Link: | RYBELSUS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RYBELSUS
Generic Entry Date for RYBELSUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RYBELSUS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alzheimer's Association | Phase 2 |
Rutgers, The State University of New Jersey | Phase 2 |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 |
Pharmacology for RYBELSUS
Drug Class | GLP-1 Receptor Agonist |
Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Paragraph IV (Patent) Challenges for RYBELSUS
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RYBELSUS | Tablets | semaglutide | 3 mg, 7 mg and 14 mg | 213051 | 1 | 2024-07-15 |
US Patents and Regulatory Information for RYBELSUS
RYBELSUS is protected by eleven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RYBELSUS is ⤷ Subscribe.
This potential generic entry date is based on patent 10,933,120.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-003 | Sep 20, 2019 | RX | Yes | Yes | 11,382,957 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-003 | Sep 20, 2019 | RX | Yes | Yes | 11,759,502 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-003 | Sep 20, 2019 | RX | Yes | Yes | 10,086,047 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RYBELSUS
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Novo Nordisk A/S | Wegovy | semaglutide | EMEA/H/C/005422 Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to |
Authorised | no | no | no | 2022-01-06 | |
Novo Nordisk A/S | Ozempic | semaglutide | EMEA/H/C/004174 Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2018-02-08 | |
Novo Nordisk A/S | Rybelsus | semaglutide | EMEA/H/C/004953 Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2020-04-03 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RYBELSUS
When does loss-of-exclusivity occur for RYBELSUS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13234496
Patent: Compositions of GLP-1 peptides and preparation thereof
Estimated Expiration: ⤷ Subscribe
Patent: 17251814
Patent: Compositions of GLP-1 peptides and preparation thereof
Estimated Expiration: ⤷ Subscribe
Brazil
Patent: 2014023374
Patent: composições de peptídeos de glp-1 e preparação das mesmas
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 68188
Patent: COMPOSITIONS DE PEPTIDES GLP-1 ET LEUR PREPARATION (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
China
Patent: 4203266
Patent: Compositions of GLP-1 peptides and preparation thereof
Estimated Expiration: ⤷ Subscribe
Patent: 7812181
Patent: GLP‑1肽组合物及其制备 (Compositions of GLP-1 peptides and preparation thereof)
Estimated Expiration: ⤷ Subscribe
Croatia
Patent: 0181447
Estimated Expiration: ⤷ Subscribe
Patent: 0231060
Estimated Expiration: ⤷ Subscribe
Cyprus
Patent: 20767
Estimated Expiration: ⤷ Subscribe
Denmark
Patent: 27885
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 27885
Patent: COMPOSITIONS DE PEPTIDES GLP-1 ET LEUR PRÉPARATION (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 88857
Patent: COMPOSITIONS DE PEPTIDES GLP-1 ET LEUR PRÉPARATION (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 24475
Patent: COMPOSITIONS DE PEPTIDES GLP-1 ET LEUR PRÉPARATION (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Hungary
Patent: 39406
Estimated Expiration: ⤷ Subscribe
Patent: 62740
Estimated Expiration: ⤷ Subscribe
Israel
Patent: 4228
Patent: תכשירים של פפטידים 1 - glp והכנתם (Compositions of glp-1 peptides and preparation thereof)
Estimated Expiration: ⤷ Subscribe
Japan
Patent: 01158
Estimated Expiration: ⤷ Subscribe
Patent: 15512374
Patent: GLP−1ペプチドの組成物、及びその調製
Estimated Expiration: ⤷ Subscribe
Lithuania
Patent: 27885
Estimated Expiration: ⤷ Subscribe
Malaysia
Patent: 1146
Patent: COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF
Estimated Expiration: ⤷ Subscribe
Mexico
Patent: 3067
Patent: COMPOSICIONES DE PEPTIDOS DE GLP-1 Y PREPARACIONES DE LAS MISMAS. (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF.)
Estimated Expiration: ⤷ Subscribe
Patent: 14010685
Patent: COMPOSICIONES DE PEPTIDOS DE GLP-1 Y PREPARACIONES DE LAS MISMAS. (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF.)
Estimated Expiration: ⤷ Subscribe
Poland
Patent: 27885
Estimated Expiration: ⤷ Subscribe
Patent: 88857
Estimated Expiration: ⤷ Subscribe
Portugal
Patent: 27885
Estimated Expiration: ⤷ Subscribe
Russian Federation
Patent: 41198
Patent: КОМПОЗИЦИИ GLP-1 ПЕПТИДОВ И ИХ ПОЛУЧЕНИЕ (GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION)
Estimated Expiration: ⤷ Subscribe
Patent: 14141700
Patent: КОМПОЗИЦИИ GLP-1 ПЕПТИДОВ И ИХ ПОЛУЧЕНИЕ
Estimated Expiration: ⤷ Subscribe
Serbia
Patent: 727
Patent: KOMPOZICIJE GLP-1 PEPTIDA I NJIHOVO DOBIJANJE (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 460
Patent: KOMPOZICIJE GLP-1 PEPTIDA I NJIHOVA PRIPREMA (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Slovenia
Patent: 27885
Estimated Expiration: ⤷ Subscribe
South Africa
Patent: 1406250
Patent: COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF
Estimated Expiration: ⤷ Subscribe
South Korea
Patent: 2072202
Estimated Expiration: ⤷ Subscribe
Patent: 2266299
Estimated Expiration: ⤷ Subscribe
Patent: 140138873
Patent: COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 200013078
Patent: GLP-1 펩티드의 조성물 및 그것의 제조 (-1 COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
Estimated Expiration: ⤷ Subscribe
Spain
Patent: 90553
Estimated Expiration: ⤷ Subscribe
Patent: 52874
Estimated Expiration: ⤷ Subscribe
Ukraine
Patent: 3976
Patent: КОМПОЗИЦІЯ СОЛІ N-(8-(2-ГІДРОКСИБЕНЗОЇЛ)АМІНО)КАПРИЛОВОЇ КИСЛОТИ І ПЕПТИДУ GLP-1
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RYBELSUS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2690553 | ⤷ Subscribe | |
Slovenia | 2991671 | ⤷ Subscribe | |
Japan | 6672140 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RYBELSUS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1863839 | 661 | Finland | ⤷ Subscribe | |
1863839 | 22/2018 | Austria | ⤷ Subscribe | PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212 |
1863839 | 2018C/016 | Belgium | ⤷ Subscribe | PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
RYBELSUS Market Analysis and Financial Projection Experimental
More… ↓